184 related articles for article (PubMed ID: 31673656)
1. A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer.
Hathout L; Mahmoud O; Wang Y; Vergalasova I; Barkati M; Després P; Martin AG; Foster W; Lacroix F; Delouya G; Taussky D; Morton G; Vigneault E
Adv Radiat Oncol; 2019; 4(4):631-640. PubMed ID: 31673656
[TBL] [Abstract][Full Text] [Related]
2. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study.
Reynaud T; Hathout L; Carignan D; Barkati M; Martin AG; Foster W; Lacroix F; Delouya G; Taussky D; Morton G; Vigneault E
Brachytherapy; 2021; 20(6):1090-1098. PubMed ID: 34238688
[TBL] [Abstract][Full Text] [Related]
3. Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost.
Ben Aicha I; Hathout L; Carignan D; Després P; Lavallée MC; Aubin S; Beaulieu L; Lacroix F; Foster W; Martin AG; Vigneault E
Brachytherapy; 2020; 19(5):584-588. PubMed ID: 32928485
[TBL] [Abstract][Full Text] [Related]
4. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.
Morton G; Chung HT; McGuffin M; Helou J; D'Alimonte L; Ravi A; Cheung P; Szumacher E; Liu S; Al-Hanaqta M; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2017 Jan; 122(1):87-92. PubMed ID: 27823821
[TBL] [Abstract][Full Text] [Related]
5. A single institutional experience with definitive radiotherapy for cervical cancer using both high- and low-dose-rate brachytherapy.
Gerszten K; Gooding WE; Lin Y; Heron DE; Faul C
Gynecol Oncol; 2006 Sep; 102(3):500-7. PubMed ID: 16503346
[TBL] [Abstract][Full Text] [Related]
6. Health-Related Quality of Life and Toxicity After Definitive High-Dose-Rate Brachytherapy Among Veterans With Prostate Cancer.
Harris AA; Yasuda M; Wu MS; Deirmenjian JM; Farooq A; Baldea KG; Flanigan R; Harkenrider MM; Welsh JS; Solanki AA
Fed Pract; 2021 Aug; 38(Suppl 3):S52-S56. PubMed ID: 34733096
[TBL] [Abstract][Full Text] [Related]
7. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
[TBL] [Abstract][Full Text] [Related]
9. DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.
Carignan D; Lessard T; Villeneuve L; Desjardins S; Magnan S; Després P; Martin AG; Foster W; Guillemette C; Lévesque É; Vigneault E
Prostate; 2020 May; 80(8):632-639. PubMed ID: 32201973
[TBL] [Abstract][Full Text] [Related]
10. Early toxicity and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer.
Gaudet M; Pharand-Charbonneau M; Desrosiers MP; Wright D; Haddad A
Brachytherapy; 2018; 17(3):524-529. PubMed ID: 29482918
[TBL] [Abstract][Full Text] [Related]
11. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial.
Corkum M; Loblaw A; Hasan Y; Chung HT; Tseng CL; McGuffin M; Cheung P; Szumacher E; Liu S; Chu W; Zhang L; Mamedov A; Morton G
Radiother Oncol; 2021 Mar; 156():160-165. PubMed ID: 33359269
[TBL] [Abstract][Full Text] [Related]
12. Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.
Contreras JA; Wilder RB; Mellon EA; Strom TJ; Fernandez DC; Biagioli MC
Int Braz J Urol; 2015; 41(1):40-5. PubMed ID: 25928509
[TBL] [Abstract][Full Text] [Related]
13. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
[TBL] [Abstract][Full Text] [Related]
14. Comparison of patient-reported acute urinary and sexual toxicity scores in a 6- versus 2-fraction course of high-dose-rate prostate brachytherapy monotherapy.
Ragab O; Banerjee R; Park SJ; Patel S; Zhang M; Wang J; Velez M; Demanes DJ; Kamrava M
J Med Imaging Radiat Oncol; 2018 Feb; 62(1):109-115. PubMed ID: 28856847
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores.
Morgan TM; Rossi PJ; Cutrell PK; Zhang C; Press RH; Rahnema S; Sanda M; Pattaras J; Cimmino C; Hershatter B; Jani AB; Patel PR
Brachytherapy; 2019; 18(6):793-799. PubMed ID: 31337543
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
17. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
[TBL] [Abstract][Full Text] [Related]
18. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
19. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial.
Gomez-Iturriaga A; Casquero F; Pijoan JI; Minguez P; Espinosa JM; Irasarri A; Bueso A; Cacicedo J; Buchser D; Bilbao P
Radiother Oncol; 2018 Feb; 126(2):278-282. PubMed ID: 29153462
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands.
Press RH; Morgan TM; Cutrell PK; Zhang C; Chen Z; Rahnema S; Sanda M; Pattaras J; Patel P; Jani AB; Rossi PJ
Brachytherapy; 2019; 18(1):13-21. PubMed ID: 30262410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
